Sun Pharmaceutical Industries Limited (“Sun Pharma”) today announced that shareholders of Organon & Co have approved the proposals related to the previously announced merger transaction under which Organon is expected to become a wholly owned subsidiary of Sun Pharmaceutical Holdings USA, Inc, an indirect wholly owned subsidiary of Sun Pharma. The shareholder approval represents a significant milestone in the proposed acquisition process and reflects continued progress towards completion of the transaction. The acquisition remains subject to the fulfilment of customary closing conditions, including receipt of applicable regulatory approvals and other necessary clearances.
Sun Pharma had announced the proposed transaction on April 27, 2026, outlining its strategic intent to expand its global pharmaceutical portfolio and strengthen its position across key therapeutic areas and international markets. The completion of the transaction will mark an important step in the company’s ongoing growth strategy, focused on enhancing its capabilities in innovative medicines and expanding access to high-quality healthcare solutions worldwide.
With a strong global presence and a diversified product portfolio, Sun Pharma is one of the world’s leading pharmaceutical companies, operating across Innovative Medicines, Generics, and Consumer Healthcare segments. The company is the largest pharmaceutical company in India and ranks among the leading generic pharmaceutical companies in the United States and global emerging markets.
Sun Pharma’s Global Innovative Medicines business continues to grow across specialty areas, including dermatology, ophthalmology, and onco-dermatology, contributing approximately 22% of the company’s sales. Through continued investment in research, development, and innovation, the company is focused on bringing differentiated therapies to patients across global markets.
The company’s vertically integrated operations enable it to develop, manufacture, and deliver high-quality medicines trusted by physicians and patients in more than 100 countries. Sun Pharma operates manufacturing facilities across five continents, supported by a diverse workforce comprising professionals from more than 50 countries.
Commenting on the development, a Sun Pharma spokesperson said, “The approval from Organon’s shareholders is an important step towards completing the proposed transaction. We appreciate the support received from stakeholders and remain focused on completing the remaining regulatory and closing requirements. The acquisition aligns with our strategy of strengthening our global pharmaceutical capabilities and expanding our ability to serve patients worldwide.”
The proposed acquisition is expected to complement Sun Pharma’s existing business strengths while creating opportunities for broader market reach, enhanced capabilities, and long-term growth. The company continues to focus on delivering innovative, accessible, and high-quality healthcare solutions while maintaining its commitment to operational excellence and sustainable value creation.
Sun Pharma is one of the world’s leading specialty generic pharmaceutical companies, with a strong presence across innovative medicines, generics and consumer healthcare products. The company is India’s largest pharmaceutical manufacturer and ranks among the leading generic drug companies in the United States and several emerging markets.
Its global innovative medicines portfolio includes products in dermatology, ophthalmology and onco-dermatology, while its vertically integrated manufacturing network spans five continents and supplies medicines to more than 100 countries. With a workforce representing over 50 nationalities, Sun Pharma continues to strengthen its global footprint by delivering quality medicines that address evolving healthcare needs across diverse markets.
